论文部分内容阅读
目的:观察重组人干扰素α2b注射液雾化吸入治疗病毒性疾病的疗效。方法:选择我院收治的50例病毒性疾病患者作为观察对象,收治时间为2015年4月至2015年12月,将其随机分成两组,对照组25例采用一般治疗,实验组在对照组基础上加用重组人干扰素α2b注射液雾化吸入治疗,观察两组病毒性疾病患者的症状缓解时间及治疗有效率。结果:对照组治疗有效率(64.00%)与实验组(88.00%)存在差异,且两组症状缓解时间存在显著差异(P<0.05),统计学有意义。结论:针对病毒性疾病患者采用重组人干扰素α2b注射液雾化吸入治疗的效果显著,安全可靠,值得推广。
Objective: To observe the efficacy of recombinant human interferon α2b injection in the treatment of viral diseases. Methods: Fifty patients with viral diseases admitted to our hospital were selected as the observation subjects. The patients were randomly divided into two groups from April 2015 to December 2015. The control group of 25 patients were treated with general treatment. The experimental group in the control group Based on the addition of recombinant human interferon α2b injection atomization inhalation treatment, the two groups of patients with viral disease symptoms and treatment of remission time and treatment efficiency. Results: The effective rate of the control group (64.00%) was significantly different from that of the experimental group (88.00%), and there was significant difference between the two groups in the symptom relief time (P <0.05). Conclusion: The treatment of patients with viral diseases using recombinant human interferon α2b injection of atomization inhalation therapy is effective, safe and reliable, it is worth promoting.